



- to be acquired by Omni Market Tide Ltd

Medical Imaging Software

Corporate Presentation

Disclaimer

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of Omni Market Tide Limited or ImExHS or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. This Presentation does not purport to contain all the information that a prospective investor may require. The Information may not be appropriate for all persons and it is not possible for Omni Market Tide Limited or ImExHS to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information. Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Before acting in reliance on any Information, the Recipient should conduct their own investigation and analysis in relation to the investment opportunity presented by this Presentation and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of Omni Market Tide Limited or ImExHS are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and Omni Market Tide Limited or ImExHS may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information.

The Information is for informational purposes only and does not constitute an offer to issue, or arrange to issue, securities or other financial products. The Information is not, and should not be construed to be, a Prospectus.

To the maximum extent permitted by law none of Omni Market Tide Limited or ImExHS or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.

Company Highlights

- Next generation Radiology and Imaging Software platform
- Established in 2012
- Operations in Colombia, Mexico, Costa Rica, Ecuador and Peru
- \$12m total future contracted revenue
- To date the renewal rate on SaaS contracts has been 100%
- Expansion into neighbouring LATAM countries with low risk go-to-market strategy
- First collaboration in Australia planned in 2018
- Additional cutting-edge functionality to be released - Web MPR Q4 2018 & Web 3D Q1 2019
- Apply for FDA approval in 2018, ahead of USA soft launch in H1 2019


Overview

OVERVIEW – PRO-FORMA

Issue Price	\$0.025
Market Capitalisation	\$22.1m
Cash (Pro-forma)	\$6.15m
Shares on Issue	885.6m
- Quoted	355.6m
- Escrowed (12 to 24 months)	530m
Milestone Options (2 Tranches)	100m
Options	130m

Revenue – 5 Years

\$AUD



Terms of Acquisition

Consideration for ImExHS

- 520 million ordinary shares
- 50 million options
 - Exercisable at 5c, expiring 30 June 2021

Performance Milestones

- 50 million options
 - Exercisable at 3.75c, expiring 5 years from grant date, vesting subject to ImExHS achieving an EBIT exceeding \$5,000,000 in any rolling period of four quarters
- 50 million options
 - Exercisable at 3.75c, expiring 5 years from grant date, vesting subject to ImExHS achieving an EBIT exceeding \$7,500,000 in any rolling period of four quarters

Advisory Options

- 30 million Advisor options
 - Exercisable at 5c, expiring 30 June 2021

Consulting Shares

- 10 million ordinary shares

Proposed Board & Key Management

DR. GERMAN ARANGO
CEO, Director

- Professor of Neuro-Radiology
- Entrepreneur with > 10 years experience running Radiology businesses
 - ImExHS Founder

CARLOS PALACIO
Non-Executive Director

- Founder and CEO of CrossPoint Telecommunications
- Managed IT and Cloud provider to multinationals across 42 countries
 - Major investor in ImExHS to date.
 - B Eng, MBA (Macquarie)

Howard Digby*
Chairman

- Company Director
- 25 year experience managing technology related businesses across Asia Pacific region
 - Senior management roles at Adobe, Gartner, Economist Group
 - B Eng (Hons) (UWA)

Andrew Lilley*
Non-Executive Director

- Company Director
- Decade of experience across the financial services industry
 - B Com, B Econ (UWA)

ANDRES VANEGAS
Chief Sales Officer


- Mechatronic Engineer
- Specialist project and service manager in Radiology industry
 - Over 10 years experience in deployment of imaging solutions for healthcare
 - Ex-CTO Fujifilm Colombia

DR. JORGE MARIN
Chief Medical Officer

- Professor of Neuro-Radiology
- Surgeon & Neuro-Radiologist Barcelona & Bogota
 - Manages ImExHS's University collaboration business agreements

*Proposal is to resign upon identifying suitable replacement board candidates

Investment Overview



Market Overview

GEOGRAPHY	MARKET (US\$m) ¹	GROWTH (CAGR) ¹
LATAM	417	8.1%
APAC	695	7.0%
North America	1,667	4.4%
Europe	967	5.8%
Other	236	6.8%
TOTAL	3,982	5.8%


- Escalating healthcare costs in all markets are driving demand for cost effective solutions
- Large percentage of radiology systems in developing countries use archaic analogue work flows, creating churn event opportunity to migrate to next-generation digital cloud solution
- Demand for web based TeleRadiology is growing rapidly (predicted CAGR of 21%²)
- The application of Artificial Intelligence to radiological interpretation creates opportunities on numerous fronts
- ImExHS is initially targeting sales expansion into neighbouring LATAM markets to where ImExHS currently operates, followed closely by APAC, then North America and finally Europe

¹ Acute Market Report (2015), Picture Archiving Communication Systems (PACS) & Radiology Information Systems (RIS), Growth, Future Prospects & Competitive Analysis, 2016 - 2026


² Future Market Insights (2017), Global Teleradiology Market Industry Analysis and Opportunity Assessment, 2016-2026

Market Opportunity - Immediate

TOTAL HOSPITALS - PUBLIC VS PRIVATE



What We Do



¹ Tele-Radiology - radiology concerned with the transmission of digitised medical images (as X-rays, CT scans, and sonograms) over electronic networks and with the interpretation of the transmitted images for diagnostic purposes

Supporting Radiologists

Hiruko supporting the efficiency and user experience for Radiologists

- Radiologists can
 - work from anywhere, on any device or browser
 - customise Hiruko to their own requirements and preferences
- The fully integrated nature of Hiruko increases both the speed and efficiency of the Radiology workflow
 - No need for the Radiologist to jump between different applications and windows
 - Second opinions can be sought from Colleagues regardless of what platform they use
- The Radiologist can use voice recognition (clinical language understanding) to append the diagnosis to the image, from anywhere on any device
- Hiruko has integrated billing including support for publically funded health insurance programs (similar to Medicare)

How We Do It

Modular

Able to grow and scale as scan volumes increase and as new diagnostic scanners or radiology facilities are added

Independent System

Hiruko can run on any infrastructure - private or public cloud and even on the customer's own dedicated server infrastructure

API Enabled

Easy to integrate with other customer or third party systems to extend its value in the customer environment

.... Compared to most RIS PACS solutions which are built on heavy, inflexible and expensive client server architecture.

Business Model

Revenue Contracts



1. Software as a Service (SaaS)
3-5 year contracts (paid monthly)



2. Platform as a Service (PaaS)
3-5 year contracts (paid monthly)



3. One-off Sales & Maintenance
Paid in Full

Target Geographies

LATAM
(Now)

APAC
(Next)

USA, Europe, Australia
(Market Driven)

Target Verticals

HEALTH CARE FACILITIES

—
Private Hospitals

Public Hospitals

Private Radiology



Distribution Model

DIRECT SALES

—
Global Growth developing
branches in each new country

Cloud Market Place Globally

Augment with channel strategy

CHANNELS

—
Specialist Distributors

TELCOs

OEMs

White Label

ImExHS Today – Value Proposition & Competitive Advantage

Radiology businesses (hospitals & clinics) prefer the ImExHS Hiruko platform because:

- Exceeds the capability & usability of competing high end platforms – Integrated Business Intelligence
- Disruptive price point – up to 75% cheaper than competitors
- Cloud-based with zero in-house IT impact
- Single end to end solution including integrated scheduling and billing tools; avoid integration of multiple solutions
- Supports non-standard file formats that have clinical significance

Radiologists love the ImExHS Hiruko platform because they can:


- Work from anywhere, using any device (Mac, PC, tablet or smartphone)
- Use speech recognition with full Clinical Language understanding embedded in the application
- Use post-processing of images to aid in diagnosis
- Efficiently consult with colleagues for second opinions
- Hiruko software is fast, stable and easy to access

ImExHS Today – Customer & Revenue Base


Solutions are fully developed, validated & proven:

- ImExHS has deployed >200 sites in LATAM
 - 71 Hospitals
 - 180 Clinics
 - > 35,000 clinical devices
 - 190 Customers
 - 5 Countries
- > 4.5 million new radiological studies per annum
- Used by over 600 Radiologists

ImExHS Today – Channel Partners



New Product Verticals



Commercialisation

- RADIOLOGY
Q4 2018 Web MPR release
Q1 2019 Web 3D release
- ANATOMICAL PATHOLOGY
Q4 2017 Secured first commercial customer
Q2 2018 Full Commercial launch
- CARDIOLOGY
Pilot testing at Las Americas
Q4 2018 Commercial launch

ImExHS Tomorrow – New Markets

	2018				2019			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
LATAM								
Brazil			Appoint Distributor	Launch				
Other South America		Appoint Distributor	Launch					
Other Central America		Appoint Distributor	Launch					
APAC								
Phillipines			Appoint Distributor	Launch				
Australia		Pilot						
APAC 2							Release	
APAC 3							Release	
NORTH AMERICA								
FDA		Submit		Approval				
USA					Soft Launch			

Medical Imaging Corporate Activity



January 2018

November 2017

November 2017

May 2017

February 2016

August 2015

UK-private equity Permira Healthcare paid \$1.3bn consideration for I-Med Radiology, Australia's largest medical imaging clinic network

Philips (mkt cap \$47bn) and Nuance (mkt cap \$6.6bn) joint-venture to bring AI into radiology reporting

Amazon (mkt cap \$843bn) partnering with Cerner Health (mkt cap \$28bn) to analyse clinical data and predict treatments using AWS cloud-hosted data

GE Health (mkt cap \$175b) and Partners HealthCare (\$12bn Revenue) 10-year joint-venture to build AI software across medical imaging software process

IBM acquired Truven Health for \$3.3bn to buy cloud-based healthcare data, analytics and insights on 200 million people

IBM acquired Merge Healthcare for \$1.25bn for medical image patient data across 7,500 US healthcare sites

Public Company Comparables

	VOLPARA (ASX:VHT)	PRO MEDICUS (ASX:PME)	ImExHS
Description	Breast X-ray imaging, transitioning to SaaS based contracts	Radiology imaging software, strong 5 year contracted revenue order book	Radiology imaging software, High growth SaaS based revenue
Market Cap (\$m)	\$105m ¹	\$845m ¹	\$22.1m ³
Cash	\$4.53m ¹	\$22.8m ²	\$6.15m ³
Revenue Growth rate (FY17 v FY16)	-22% ⁶	14.7% ⁵	37% ⁴
TRADING			
Total Contracted Revenue	\$10.2m ¹	\$125m ⁷	\$12.0m ¹
<i>Multiple</i>	10.3x	6.8x	1.8x ³
HISTORICALS			
FY17 Revenue	\$1.7m ⁶	\$31.6m ⁵	\$4.5m ⁴
<i>Multiple</i>	60.5x	28.5x	4.9x ³
FORWARD			
FY18 Revenue Forecast	\$2.96m ⁸	\$39.9m ⁹	
<i>Multiple</i>	34.5x	22.5x	

¹ 31 March 2018

² 31 December 2017

³ ImExHS as at IPO Listing

⁴ 31 December 2017

⁵ 30 June 2017

⁶ 31 March 2017

⁷ 5 March 2018

⁸ 24 January 2018, Morgans Research

⁹ 17 November 2017, Moelis Australia Research

Use of Funds

	\$6,150,000
Sales & Marketing	\$3,150,000
FDA approvals / US soft launch	\$150,000
Research & Development	\$750,000
Working Capital	\$1,089,000
Corporate and Admin Costs	\$500,000
Costs of the offer	\$511,000



Investment Highlights

- **DE-RISKED**
Future contracted revenue \$12m
- **LEADING TECHNOLOGY**
Next generation workflow and image management solution for Healthcare Facilities, built by radiologists, for radiologists
- **PROVEN**
Successfully demonstrated market penetration into Mexico, Ecuador, Peru and Costa Rica with post-raising strategies for rapid expansion in LATAM and Asia-Pacific
- **SALES PIPELINE**
Strong sales pipeline to support \$12m in contract forward revenue
- **FUNDING**
Funding largely dedicated to expansion, rather than technical development